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INTRODUCTION
The approach of using an artificial material to replace an opaque 
cornea was first described by Pellier de Quengsy, more than 200 
years ago(1). Since that time, several attempts to develop a modern 
keratoprosthesis to treat patients with corneal blindness and a poor 
prognosis for penetrating keratoplasty have been developed, with 
various models using different material, innovative designs and surgi­
cal techniques(2,3). 
Despite progress in the conception of keratoprosthesis, the hete­
rogeneity of the results related to different devices and the serious 
complications historically described, hampered the acceptance of 
the keratoprosthesis as a safe option for surgical treatment. Currently, 
however, considering modifications made to the designs, and im­
provements in surgical technique and postoperative management, 
the keratoprosthesis emerged as a viable alternative in patients at 
high risk for conventional keratoplasty(4). 
One of the most commonly used device is the Boston type I ke ­
ratoprosthesis (BKPro), developed initially by Dohlman et al., in 1974(5) 
and approved by the Food and Drug Administration in 1992. Its 
design and clinical management have undergone several important 
changes, which increased the BKPro popularity and improved its 
outcomes in the last several years. 
Boston keratoprosthesis devices
The Boston keratoprosthesis has a collar button design, made of 
polymethyl methacrylate (PMMA)(2,6). The BKPro has 2 configurations. 
The type I device, which is the most frequently used type, consists 
of a PMMA optical front plate and stem, which is inserted through a 
fresh corneal donor graft, locking into a larger back plate (Figure 1). 
It is usually recommended for patients with good lid anatomy and 
blink to preserve a healthy ocular surface(3) (Figure 2). The type II BKPro 
has a similar design, with an added 2 mm long anterior cylinder that 
protrudes through the lids or between a tarsorraphy (Figure 3). It is 
reserved for cicatrizing corneal diseases with poor tear function(2,7).
The type I BKPro dioptric power is polished into its front plate 
power, and the devices differ based on the eye phakic status: one 
design for aphakia and the other for pseudophakia. The device for 
aphakia is custom based on the axial length of the recipent eye(8).
Advances in type I BKPro design have improved its retention 
rate. The latest version approved by the Food and Drug Adminis­
tration (FDA) for marketing presents 8 holes of 1.3 mm diameter in 
the back plate to allow aqueous nutrition for the corneal button 
sandwiched between the front and back plate, protecting the tissue 
from necrosis and melt(2,9). Moreover, the addition of a titanium 
locking ring, on the portion of the front plate protruding from the 
back plate, helps to prevent latter intraocular unscrewing of the 
BKPro complex. Alternatively, the back plate can also be made of 
titanium, which seems to cause less postoperative reaction than 
PMMA(10). The titanium back plate has been studied since 2005 and 
it has been tried with 8 and 16 holes to allow a better nutrition for 
the corneal button. However, as far as we know, it has not yet been 
approved by the FDA for marketing(10).
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ABSTRACT
Regardless of significant progress in the field of corneal transplantation to treat cor­
neal opacification, some cases of corneal blindness still present a poor prognosis 
for conventional penetrating keratoplasty. In patients with repeated graft fai lure 
and/or with severe ocular surface disease, the Boston type I keratoprosthesis (type I 
BKPro) has become a viable option. Modifications in its design and postoperative 
management have improved the long­term outcomes of visual acuity, retention, and 
postoperative infection rates. These advances made the type I BKPro be considered 
a safe alternative for visual rehabilitation in many patients with corneal pathologies. 
However, postoperative handle of chronic comorbidities, such as glaucoma, is still 
critical for preserving the visual gains achieved with BKPro. 
Keywords: Cornea; Corneal diseases/surgery; Prostheses and implants; Corneal trans ­
plantation; Prosthesis design
RESUMO
Apesar dos avanços consideráveis nas técnicas de transplantes da córnea para o tra ta- 
 mento de opacidades corneanas, alguns casos de cegueira de etiologia corneana ain-
da apresentam prognóstico reservado com a ceratoplastia penetrante convencional. 
Nesses pacientes, tais como aqueles vitimas de múltiplas falências após transplante 
de córnea e/ou com doença da superfície ocular avançada, a ceratoprótese de Boston 
tipo I (BKPro tipo I) tem se tornado uma opção viável. Modificações no seu modelo e no 
manejo pós-operatório melhoraram os resultados de acuidade visual, retenção e taxas 
de infecção pós-operatória a longo prazo. Devido às melhorias no dispositivo, a BKPro 
tipo I tem sido considerada uma alternativa cirúrgica segura para a reabilitação visual 
em muitos pacientes com patologias corneanas avançadas. Contudo, o controle pós-
ope ratório de co-morbidades crônicas, como glaucoma, é fundamental para preservar 
os ganhos visuais obtidos com a BKPro. 
Descritores: Córnea; Doenças da córnea/cirurgia; Próteses e implantes; Desenho de 
prótese
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indications
The type I BKPro is indicated for patients with refractory corneal 
blindness and poor prognosis for penetrating keratoplasty. It is usually 
reserved for patients with multiple graft failure and those with ocu­
lar surface disease in which conventional corneal transplantation is 
considered of high risk(11). 
Although the most favorable BKPro indications are multiple fai­
led corneal grafts(12), other ocular conditions have been suitable for 
BKPro use. Expanding indications include cases of ocular trauma, 
chemical burns(13), herpetic keratitis(14), aniridia(15), pediatric corneal 
opacities(16), autoimmune ocular disorders, and severe corneal vas­
cularization(17­20) (Table 1). The expected outcomes are influenced by 
the primary indication, with best results observed in non­cicatrizing 
conditions, while patients with autoimmune diseases, such as 
Stevens­Johnson syndrome (SJS), usually present a less encouraging 
prognosis(12).  
Until recently, taking into account the high risk of postoperative 
complications, the BKPro implantation was reserved for cases with 
advanced bilateral disease, and thus, good visual acuity in the fellow 
eye was considered a relative contra­indication for the procedure(12). 
However, considering the advances in the postoperative manage­
ment, reducing drastically the rate of complications(2), the BKPro has 
now been implanted in patients with unilateral visual impairment 
with good results in terms of binocular function restoration(4,21). 
surgical procedure
The technique for implanting the type I BKPro has been pre­
viously described by Dohlman et al.(22). First of all, a corneal donor 
button is prepared (8.5 ­ 9.0 mm) and a central 3 mm hole is tre­
phined. For better BKPro centration the 3 mm central trephination 
can be performed before the outer diameter punch is used(23). The 
donor button is then placed over the stem of the front plate, and the 
back plate is placed on top of this complex. A titanium locking ring 
is then snapped into place. The recipient cornea is prepared as for 
traditio nal penetrating keratoplasty, with a usual host trephine mea­
suring 0.5 mm less in diameter than the donor graft. The donor button 
is then sutured with multiple interrupted 10­0 nylon stitches(11). 
In phakic patients, lens extraction is necessary at the time of 
BKPro implantation. If pseudophakic, the intraocular lens (IOL) can be 
left in place or explanted, depending on the IOL stability. If aphakic, 
a core anterior vitrectomy is generally performed. At the end of the 
procedure, a soft contact lens is placed. 
postoperative management and complications
Postoperative care includes the use of soft contact lens over the 
keratoprosthesis in all patients for an indefinite time, with regular 
replacement. The addition of a continue use of a bandage contact 
lens over the BKPro has been of great benefit for better hydrata­
tion of the exposed tissues, enhancing the device retention and 
preven ting complications as dellen formation, epithelial defects and 
corneal melt(2). 
Postoperatively, all patients need a topical regimen of steroids 
with dosage tapering over the first weeks. A maintenance dose can 
be adopted according to levels of intraocular inflammation. 
An indefinitely prophylactic antibiotic regimen is recommended 
for infectious complications prevention. The recommended prophy­
laxis routine includes the use of daily topical fluoroquinolone drops, 
with a recent addition of topical 1.4% vancomycin, especially in cases 
of autoimmune diseases(2). The inclusion of topical vancomycin to 
the standard prophylactic regimen has dramatically reduced the 
incidence of bacterial endophthalmitis in BKPro eyes(24).
The continued use of bandage contact lenses and the long­term 
use of broad­spectrum antibiotics and corticosteroids, however, have 
the potential of altering the ocular microbiota and predispose fun­
gal colonization. Considering the low rate of fungal infection, there 
Figure 1. Boston type I keratoprosthesis. (Courtesy of Claes H. Dohlman MD, PhD).
Figure 2. Clinical aspect of Boston type I keratoprosthesis.
Figure 3. Boston type II keratoprosthesis. (Courtesy of Claes H. Dohlman MD, PhD).
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is no literature support for addition of a chronic topical anti­fungal 
prophylaxis in the routine management of KPro patients, but a short 
course of topical amphotericin might be considered in patients with 
proven fungal colonization(25). Also, the addition of monthly topical 
5% povidone­iodine in the postoperative care routine might be an 
alternative for preventing fungal colonization(26). 
In the past, the most common complications of a BKPro were 
melt around the BKPro interface, leakage of aqueous, instability of 
the device, glaucoma, retinal detachment, infectious keratitis, and 
the most frightening of all, endophthalmitis(2).
Many of the serious complications are frequently seen in the first 
year of surgery. The greatest vision­threatening risk facing patients 
with any type of keratoprosthesis is bacterial endophthalmitis, most 
cases associated with Gram­positive pathogens(2,24,27). Early recogni­
tion and aggressive treatment are crucial for favorable results in 
the ses cases(28). Since 1990, topical antibiotic prophylaxis has been 
used to prevent bacterial endophthalmitis in patients with the Bos­
ton KPro(25). The topical recommend regimen of 0.5% moxifloxacin 
or 0.3% gatifloxacin associated with 1.4% vancomycin reduced the 
incidence of endophthalmitis since last decade(2). 
Nowadays, one of the most common BKPro problems is the de ve­
lopment of a retroprosthetic membrane (RPM), occurring in 25­65% 
of patients within a year after the device implantation(29). It can usually 
be treated with yttrium­aluminum­garnet (YAG) laser membrano­
tomy, with few cases requiring a surgical mebranectomy(11). The 
etio logy of RPM is unknown; authors have reported that the perfor­
mance of other intraocular surgery at the time of keratoprosthesis 
implantation(4), increased anterior segment inflammation(17), diabe­
tes, hypertension(30), and race(30), increase the risk of RPM formation(31). 
Results from a Multicenter Study regarding this issue reported that 
eyes at the highest risk for retroprosthetic membrane development 
are those receiving corneal replacement for infectious keratitis and 
aniridia.(y) Stacy et al., characterized retroprosthetic membrane as a 
fibrous membrane originated from the host’s corneal stroma by light 
microscopy. This data suggest that stromal downgrowth might be 
the major element of the retro KPro membranes(32).
The visual recovery and long term outcomes of BKPro patients 
can also be severely limited by retina and glaucoma pathologies. 
Posterior segment abnormalities may be present prior to BKPro im ­
plantation or may occur during or after the surgical procedure(33). 
The related incidence of retinal detachment after BKPro implanta­
tion range from 3.5 to 8% of cases(11,4). Modified vitreoretinal surgical 
techniques, due to anatomical difficulties frequently encountered 
during surgical procedure, can be effectively and safely used to treat 
posterior segment complications in these patients(33).
Glaucoma can severely compromise visual rehabilitation. The 
onset and/or progression of glaucoma remain ongoing challenges 
in the management of patients with BKPro(34). The diagnosis of glau­
coma in these patients is made difficult by the absence of a reliable 
tool to measure the intraocular pressure (IOP), with digital finger 
pal pation being the most used method of estimating the IOP(34). 
Ri gorous perioperative management of elevated IOP is essential 
for long­term success of BKPro surgery(35). These patients should be 
followed closely by a multidisciplinary team, including glaucoma and 
retina specialists. Regular visual fields and photo documentation of 
the optic nerve should be performed. 
Besides medical hypotensive treatment, glaucoma drainage de vi ces 
or cyclophotocoagulation procedures have been used to address 
this potential complication(36,37). Considering that standard glaucoma 
shunts are often susceptible to capsule fibrosis obstructing the tube 
flow, efforts have been made to produce modified tube devices, 
such as Ahmed valve shunts to divert aqueous humor to alternative 
epithelialized cavities (lacrimal sac and ethmoid sinuses) where an 
obstructing capsule is less likely to form obstructing the flow and 
consequently increasing the intraocular pressure(38). Randomized 
studies with longer follow­up, though, are necessary to address con­
cerns about a possible increase incidence of infectious complica tions 
and hypotony in theses modified drainage devices. 
RESULTS
Several studies have been published to report the outcomes 
with Boston type I keratoprosthesis (Table 2). Results from the first 
multicenter study, including 136 eyes with this device, were relevant 
diffusing this surgical technique, demonstrating improvements in 
the retention rate (95% in 8.5 months of follow­up) and in the visual 
prognosis(11). The main postoperative complication observed was 
RPM formation (25%), followed by an increase of IOP (15%). There 
were no reported cases of endophthalmitis after surgery. Conside­
ring the study group preoperative characteristics, better outcomes 
were observed in patients previously diagnosed with multiple graft 
failure and chemical burns, compared with patients with cicatricial 
conjunctivitis (SJS and OCP). 
Aldave et al., (4) found similar results with type I BKPro regarding 
anatomical retention and visual acuity improvement in 50 eyes of 
49 patients. The most common complications were RPM (44%) and 
persistent epithelial defects (38%). In this study, with an average 
follow­up of 17 months, there were no cases of endophthalmitis. 
In 2010, Dunlap et al., reported good short­term visual outcomes 
of BKPro implantation in 126 eyes(39). Eighty­two percent of these 
cases improved visual acuity within 6 months after surgery, with 
mean spherical refractive error of 0.57 diopters (D) and a mean as ­
tig matism of 0.10 D. 
Bradley et al.(40), analyzed 30 eyes of 28 patients undergoing im ­
plantation of type I BKPro with a mean follow­up of 19 months. The 
anatomical retention rate was 81.3% and final visual acuity ≥ 20/200 
Table 1. Boston type I keratoprosthesis expanding indications
Diagnostic  
indication
N 
eyes
Mean follow-up 
(months)
Preoperative 
VA>20/200
Latest
VA>20/200
Retention 
rate
Khan et al.(14) Herpetic keratitis 17 14 (6­72) 5% 76% 100%
Akpek et al.(15) Aniridia 16 17 (2­85) 0% 62% 100%
Aquavela et al.(16) Pediatric CO 21 9.7 (1­30) NI 9.5% (NA: 66%) 100%
Sayegh et al.(17)* SJS 16 43.2 (10­67) 0% 50% 100%
Sejpal et al.(18)** Corneal LSCD 23 22.1 (0.5­58.6) 4.3% NI*** 73.9%
VA= visual acuity; CO= corneal opacity; NI= not informed; NA= not applicable; SJS= Stevens­Johnson syndrome; LSCD= limbal stem 
cell deficiency
*= ten eyes underwent type II BKPro, whereas six eyes underwent type I BKPro
**= etiologies for LSCD were chemical injury (30.4%), SJS (26.1%), aniridia (13.1%), topical medication toxicity (13.1%), mitomycin C toxicity 
(8.7%), mucous membrane pemphigoid (4.3%) and chronic keratitis (4.3%)
***= VA was 20/50 or better in 67% of eyes 3 years after keratoprosthesis implantation
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observed in 77% of eyes. Glaucoma and posterior segment patho­
logies were the main causes of poor visual acuity improvement. 
RPM was also considered the most frequent complication (43%). 
Three patients (10%) had endophthalmitis despite the correct use of 
postoperative medications (including 1.4% vancomycin eye drops). 
At the same center, in a longer follow­up, Greiner et al.(41), found 
that a significant number of patients can decrease vision during the 
postoperative course. End­stage glaucoma was the most commonly 
cause of visual loss when best corrected visual acuity (BCVA) > 20/200 
was not retained. 
Future perspectives
Considering the important reduction in acute complications re ­
lated to type I BKPro implantation, attention should be focused on 
its long­term visual outcomes. Currently, BKPro results are still limited 
by chronic comorbidities, such as glaucoma. Improvements and 
de velopments on IOP measurements devices are necessary. Several 
attempts for new methods to monitor IOP have been made. Tele­
metric IOP measurement allows monitoring of IOP in patients who 
cannot be measured by current methods, such as patients with kera­
toprosthesis. A recent experimental study of telemetric IOP records 
used a wireless transducer implanted in rabbits after extracapsular 
lens extraction demonstrating concordance with direct manometry 
measures(42). Further studies are necessary, however, to validate its 
use and safety in human eyes. 
Besides the significant impact of a broad­spectrum antibio­
tic routine in reducing infectious complications related to BKPro 
patients, the need of using an indefinite postoperative eye drops 
regimen may be limited by patients’ adherence and compliance. The 
creation of drug delivery systems such as a contact lens slow release 
of antibiotic might be a future option to solve this problem(43). 
Another point to be addressed is biocompatibility. Although the 
favorable retention rates demonstrated in several case series are 
encouraging, other materials such as titanium seems to be less 
problematic to corneal cells, allowing a better interaction and less in­
flammation(44). Behlau et al,, reported the potential of improving the 
biocompatibility and the potential of inhibition of bacterial biofilm 
bonding N,N­hexyl,methyl­polyethylenimine to BKPro(45). Wang et al., 
also reported encouraging biointegration results coating polymethyl 
methacrylate with hidroxyapatite. They demonstrated an enhanced 
keratocyte proliferation in porcine cornas ex vivo(46). 
In summary, over the last few decades, important advances in the 
field of keratosprosthesis implantation were demonstrated. Despite 
of that, for good long­term results, it is imperative that a multidis­
ciplinary team carefully monitor all patients submitted to this pro­
cedure, with regular visits and prompt support considering any kind 
of complications. Future studies, attesting the very long­term stability 
Table 2. Boston type I keratoprosthesis literature outcomes
N 
eyes
Mean follow-up 
(months)
Preoperative 
VA>20/200
Latest
VA>20/200
Retention 
rate Complications
Zerbe et al.(11) 141 8.5 3.6% 56% 85% RPM (25%) 
High IOP (15%)
Aldave et al.(4) 50 17 10% 82%* 84% RPM (44%) 
PED (38%)
Bradley et al.(40) 30 19 17% 77% 81.3% RPM (43%) 
High IOP (27%)
Endophthalmitis (10%)
Greiner et al.(41) 40 33.6 5% 50% 80% RPM (55%)
Glaucoma (27%)
Endophthalmitis (12.5%)
VA= visual acuity; RPM= retroprosthetic membrane; IOP= intraocular pressure; PED= persistent epithelial defects
*= visual acuity at one year of follow­up
and visual maintenance are still pending. At this point, however, the 
literature results are very encouraging to use the type I BKPro as 
a viable option for visual rehabilitation in patients with advanced 
corneal disease.
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